Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.58 |
| ▸ | CA2 | P00918 | 2/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ACP3 | P15309 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19728201 | 0.84 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11938486 | 0.84 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3695690 | 0.84 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL19728209 | 0.84 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL11938484 | 0.84 | CA1 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL120187 | 0.84 | CA12 (0.58) | CA1CA2CA12CA7CA9 | |
| SCHEMBL343939 | 0.82 | CA1 (0.55) | CA1CA2CA12CA7CA9 | |
| SCHEMBL3071819 | 0.82 | CA1 (0.55) | CA1CA2CA12CA7CA9 | |
| SCHEMBL931283 | 0.82 | CA1 (0.55) | CA1CA2CA12CA7CA9 | |
| SCHEMBL19315897 | 0.80 | CA12 (0.52) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3248969-B1 | PROCESS FOR THE PREPARATION OF N-[3-(AMINOMETHYL)OXETAN-3-YL]CARBAMATE INTERMEDIATES | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | claimed |
| EP-2844065-A2 | ATTRACTANT COMPOSITION | Attratec GmbH (DE) | 2015-03-11 | — | — | EP | claimed |
| WO-2013164426-A2 | ATTRACTANT COMPOSITION | ATTRATEC GMBH (DE) | 2013-11-07 | — | — | WO | claimed |
| EP-4531799-A1 | TWO-STAGE DYEING METHOD FOR IMPROVED DYEING OF HAIR WITH NATURAL DYES | Henkel AG & Co. KGaA (DE) | 2025-04-09 | — | — | EP | disclosed |
| EP-3701005-B1 | SOLID FRAGRANCE-CONTAINING COMPOSITION | HENKEL AG & CO KGAA (DE) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023227292-A1 | TWO-STAGE DYEING METHOD FOR IMPROVED DYEING OF HAIR WITH NATURAL DYES | HENKEL AG & CO. KGAA (DE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION | 2023-11-02 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | US | disclosed |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VLAHOV IONTCHO R | 2010-01-07 | — | — | US | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | ENDOCYTE, INC. | 2008-11-13 | — | — | US | disclosed |
| EP-1859954-B1 | Planographic printing plate precursor and stack thereof | FUJIFILM CORP (JP) | 2008-11-12 | — | — | EP | disclosed |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | ENDOCYTE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | ENDOCYTE, INC. | 2008-10-09 | — | — | US | disclosed |
| CN-1096700-A | Medicine for treating calculus | WANG TIE (CN) | 1994-12-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293497-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA1 431/4885CA2 1961/4885CA12 58/4885 |
| US-20100004276-A1 | VITAMIN RECEPTOR BINDING DRUG DELIVERY CONJUGATES | VDR, CYP2R1, CYP24A1 | CA1 4008/4885CA2 2790/4885CA12 3414/4885 |
| US-20080248052-A1 | Vitamin receptor binding drug delivery conjugate | VDR, HCAR1, FOLR1 | CA1 3219/4885CA2 2485/4885CA12 2042/4885 |
| US-20080280937-A1 | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives | VDR, HCAR1, FOLR1 | CA1 1867/4885CA2 3559/4885CA12 1649/4885 |
| US-20100324008-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA1 431/4885CA2 1961/4885CA12 58/4885 |
| US-11717514-B2 | PSMA binding ligand-linker conjugates and methods for using | FOLH1, KLK3, PSMA1 | CA1 431/4885CA2 1961/4885CA12 58/4885 |
| US-20230346752-A1 | PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING | FOLH1, KLK3, PSMA1 | CA1 431/4885CA2 1961/4885CA12 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.